To date, the most frequently reported resistance mechanisms to second-line osimertinib, including analyses of circulating-tumor DNA (ctDNA) samples from patients in the Phase III AURA3 study are acquired EGFR mutations (e.g., C797S), and amplification of MET and ERBB2 (HER2)13–15. The gene discussed is EGFR; the disease is neoplasm.